Price History

Hover for the daily close. The dotted line marks the period open.

Compare GOSS with… →

GOSS Key Statistics

As of Sep 4, 2026

Trading

Open: $0.17
Previous Close: $0.18
Day's Range: 0.17–0.18
52-Week Range: 0.11–3.87
Volume: 8.06M
Beta: 2.00

Valuation

Market Cap: $85.69M
P/E Ratio: unprofitable
P/S ratio: 1.61
EPS (ttm): −0.66

Financials (FY)

Revenue (FY): $48.47M−57.74%
Net Income (FY): −$170.37M
Profit margin: −235.00%
Shares Outstanding: 488.85M
1-Year Return: −93.03%

Dividend and dates

Earnings Date: November 4, 2026estimated
Avg Volume: 27.68M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

GOSS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−12.88%−38.13%+16.96%−80.81%−57.93%−0.88%+242.54%−94.35%

2019*2020202120222023202420252026*

Year	Return
2026 (partial year)	−94.35%
2025	+242.54%
2024	−0.88%
2023	−57.93%
2022	−80.81%
2021	+16.96%
2020	−38.13%
2019 (partial year)	−12.88%

As of September 4, 2026.

GOSS Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$48.47M	−$170.37M	−351.5%
2024	$114.70M	−$56.53M	−49.3%
2023	$0.00	−$179.82M	—
2022	$0.00	−$229.38M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$48.47M	—	−$163.25M	−$170.37M	−351.5%
2024	$114.70M	—	−$59.92M	−$56.53M	−49.3%
2023	$0.00	—	−$173.76M	−$179.82M	—
2022	$0.00	—	−$218.53M	−$229.38M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GOSS Valuation vs Biotechnology Median

Median of 656 stocks

Metric	GOSS	Biotechnology median	vs median
P/S ratio	1.61	15.26	0.1x the median
Profit margin	−235.00%	0.00%	235.0 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Gossamer Bio, Inc. (GOSS) at $85.69M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 161 employees.

The most recent close on file for GOSS is $0.18, dated September 4, 2026. That is $0.00 (−0.57%) against the previous close. The 52-week range on file runs from $0.11 to $3.87. The latest close sits 53.51% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $48.47M. That is −57.74% against the prior fiscal year, when revenue was $114.70M. The same year closed with a net loss of $170.37M. The reported profit margin is −235%. That is 235 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.66.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $48.47M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 1.61. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −93.03%. Across 5 years the annualized return works out at −55.44%. Beta against the wider market is reported at 2. Daily returns over the trailing 7 years annualize to a volatility of 97.6%.

Growth & Income

No dividend is on file for GOSS.

The strongest complete calendar year on file is 2025 at +242.54%; the weakest is 2022 at −80.81%. Of the 6 complete calendar years on file, 2 finished higher. 2026 is still running; the price is −94.35% year to date.

Peer Comparison

Gossamer Bio, Inc. (GOSS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Gossamer Bio, Inc.	GOSS	$85.69M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Gossamer Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Visit website →

Gossamer Bio, Inc. (GOSS) Stock Analysis